Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PRKCA | P17252 | 3/20 | 0.35 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18209371 | 1.00 | DGKA (0.47) | DGKADNM1EPHX2PRKCAPAM | |
| SCHEMBL1044582 | 0.99 | DGKA (0.48) | DGKADNM1EPHX2PRKCAPAM | |
| Hydrochloric Acid SCHEMBL421819 | 0.94 | MGLL (0.46) | DGKAEPHX2PRKCAMGLLCNR2 | |
| Hydrochloric Acid SCHEMBL4074680 | 0.94 | MGLL (0.46) | DGKAEPHX2PRKCAMGLLCNR2 | |
| Water SCHEMBL6549696 | 0.92 | MGLL (0.46) | DGKAEPHX2PRKCAMGLLCNR2 | |
| Hydrochloric Acid SCHEMBL3281364 | 0.81 | MGLL (0.45) | DGKAEPHX2PRKCAMGLLCNR2 | |
| Hydrochloric Acid SCHEMBL421820 | 0.81 | MGLL (0.45) | DGKAEPHX2PRKCAMGLLCNR2 | |
| SCHEMBL19133947 | 0.79 | MGLL (0.46) | DGKAEPHX2PRKCAMGLLCNR2 | |
| SCHEMBL441410 | 0.79 | MGLL (0.46) | DGKAEPHX2PRKCAMGLLCNR2 | |
| SCHEMBL16607665 | 0.78 | DGKA (0.45) | DGKAEPHX2PRKCAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| US-20220313608-A1 | TREATMENT OF BREAST CANCER | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2022-10-06 | — | — | US | claimed |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2021-11-16 | — | — | US | claimed |
| EP-3397244-B1 | TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2021-10-06 | — | — | EP | claimed |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | YALE UNIVERSITY (US) | 2020-07-14 | — | — | US | claimed |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | NATIONAL SCIENCE FOUNDATION | 2020-06-11 | — | — | US | claimed |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | MODULATE THERAPEUTICS INC (CA) | 2019-07-11 | — | — | US | claimed |
| EP-2836234-B1 | VEHICLES FOR CONTROLLED DELIVERY OF DIFFERENT PHARMACEUTICAL AGENTS | UNIV YALE (US) | 2019-06-12 | — | — | EP | claimed |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | YALE UNIVERSITY (US) | 2019-02-05 | — | — | US | claimed |
| US-20190015332-A1 | TREATMENT OF BREAST CANCER | SynCore Biotechnology Co. Ltd. (TW) | 2019-01-17 | — | — | US | claimed |
| US-9827196-B2 | Method of administering a cationic liposomal preparation | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2017-11-28 | — | — | US | claimed |
| US-9707204-B2 | Treatment of breast cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2017-07-18 | — | — | US | claimed |
| US-9610250-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2017-04-04 | — | — | US | claimed |
| US-9603800-B2 | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels | YALE UNIVERSITY (US) | 2017-03-28 | — | — | US | claimed |
| US-20160081929-A1 | Method of Administering a Cationic Liposomal Preparation | MEDIGENE AG (DE) | 2016-03-24 | — | — | US | claimed |
| US-9233094-B2 | Method of administering a cationic liposomal preparation | MEDIGENE AG (DE) | 2016-01-12 | — | — | US | claimed |
| US-20150359778-A1 | Treatment of Triple Receptor Negative Breast Cancer | SYNCORE BIOTECHNOLOGY CO., LTD (TW) | 2015-12-17 | — | — | US | claimed |
| US-9144563-B2 | Treatment of triple receptor negative breast cancer | MEDIGENE AG (DE) | 2015-09-29 | — | — | US | claimed |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | YALE UNIVERSITY (US) | 2015-04-30 | — | — | US | claimed |
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | YALE UNIVERSITY | 2015-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | DGKA 929/4885DNM1 2959/4885EPHX2 263/4885 |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | DGKA 727/4885DNM1 2950/4885EPHX2 216/4885 |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | UACA, HLA-DRB1, TNF | DGKA 923/4885DNM1 3704/4885EPHX2 170/4885 |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | DGKA 929/4885DNM1 2959/4885EPHX2 263/4885 |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | LIPA, CD44, ABCB4 | DGKA 595/4885DNM1 4139/4885EPHX2 271/4885 |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | UACA, HLA-DRB1, TNF | DGKA 923/4885DNM1 3704/4885EPHX2 170/4885 |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | UACA, HLA-DRB1, LIPA | DGKA 866/4885DNM1 3668/4885EPHX2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.